StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
'Best-Case Exit Strategy': Biogen (BIIB) Stock Falls as Takeover Rumor Denied, But Analysts Bullish on Takeover Prospect
December 30, 2021 8:07 AM
Biogen (NASDAQ: BIIB) stock price is down over 6.5% in pre-open Thursday after Samsung Group denied it is engaged in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Mergers and Acquisitions
Next Articles
Yearly Drug Price Changes by Biogen (BIIB), Gilead (GILD), Regeneron (REGN) and Vertex (VRTX) - Truist
January 3, 2022 5:39 AM
Samsung BioLogics Said Biogen (BIIB) Buyout Rumor 'Untrue'
December 29, 2021 11:59 PM